UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
DATE OF REPORT (Date of earliest event reported): June 5, 2014
001-33635
(Commission file number)
TAXUS CARDIUM PHARMACEUTICALS GROUP INC.
(Exact name of registrant as specified in its charter)
| Delaware | 27-0075787 | |
| (State of incorporation) | (IRS Employer Identification No.) |
| 11750 Sorrento Valley Rd., Suite 250 San Diego, California 92121 |
(858) 436-1000 | |
| (Address of principal executive offices) | (Registrant’s telephone number) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
On June 5, 2014, Taxus Cardium Pharmaceuticals Group Inc. (“Taxus Cardium”) held its Annual Meeting of Stockholders. At the meeting, approximately 68% of the outstanding shares of our voting stock were represented in person or by proxy. The first proposal voted upon was the election of three Class II Directors, each to serve until the next annual meeting of stockholders held to elect Class II directors. The three persons nominated by our Board of Directors received the following votes and were elected:
| Name |
For | Withheld | Broker Non-Votes | |||
| Tyler M. Dylan-Hyde |
2,005,593 | 291,533 | 4,208,412 | |||
| Andrew M. Leitch |
1,973,470 | 293,191 | 4,208,412 | |||
| Gerald J. Lewis |
1,971,488 | 293,193 | 4,208,412 |
The second proposal voted upon was ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2014. The proposal received the following votes and was approved:
| For |
6,056,326 | |||
| Against |
369,915 | |||
| Abstain |
140,205 |
ITEM 8.01 OTHER EVENTS.
At the Annual Meeting of Stockholders held on June 5, 2014, Christopher J. Reinhard, Chairman and Chief Executive Officer of Taxus Cardium provided stockholders in attendance with a corporate overview and update. The investor presentation is available at Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CARDIUM THERAPEUTICS, INC. | ||||||
| Date: June 10, 2014 | By: | /s/ Christopher J. Reinhard | ||||
| Christopher J. Reinhard | ||||||
| Chief Executive Officer | ||||||